Data Integrity—A Study of Current Regulatory Thinking and Action | PDA Journal of Pharmaceutical Science and Technology

References

1.↵
1. Cosgrove T.
Opening Remarks. Presented at the ISPE-FDA CGMP Conference, Baltimore, MD, USA, June 2–4, 2014.
Google Scholar
2.↵
FDA Media Briefing. Commissioner Hamburg on her visit to India. http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM387679.pdf (accessed January 24, 2015).
Google Scholar
3.↵
Business Today. Compliance doesn't end with approval: US FDA commissioner. http://businesstoday.intoday.in/storyprint/203213 (accessed January 24, 2015).
Google Scholar
4.↵
1. Moore N,
2. Juillet Y,
3. Bertoye P.-H.
Intégrité des données scientifiques: transparence des données recueillies au cours des essais cliniques, accès aux données. Thérapie 2007, 62(3), 203–209.
OpenUrl PubMed Google Scholar
5.↵
1. Lindblad A. S.,
2. Manukyan Z.,
3. Purohit-Sheth T.,
4. Gensler G.,
5. Okwesili P.,
6. Meeker-O'Connell A.,
7. Ball L.,
8. Marler J. R.
Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection. Clinical Trials. 2014, 11(2), 205–217.
OpenUrl PubMed Google Scholar
6.↵
1. Takahashi K.
Data Integrity: Warning Letters. Presented at the PDA Annual Meeting, San Antonio, TX, USA, April 7–9, 2014.
Google Scholar
7.↵
GCP Inspectors Working Group. Reflection Paper on Expectations for Electronic Source Data and Data Transcribed to Electronic Data Collection Tools in Clinical Trials; EMA/INS/GCP/454280/2010: London, UK, June 9, 2010.
Google Scholar
8.↵
1. Katz P. R.
Protecting the public's health through the application integrity policy. Food & Drug Law Journal 2010, 65(3), 539–543.
OpenUrl PubMed Google Scholar
9.↵
1. Rosa C.
Current Inspectional & Compliance Issues in Data Integrity. Presented at the ISPE-FDA CGMP Conference, Baltimore, MMD, USA, June 2–4, 2014.
Google Scholar
10.↵
1. Rosa C.
ICH Q7 Principles and Data Integrity. Presented at the PDA-PIC/S Training on ICH Q7, Bethesda, MD, USA, February 2014.
Google Scholar
11.↵
MHRA News. MHRA expectation regarding self-inspection and data integrity. http://webarchive.nationalarchives.gov.uk/20141205150130/ http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodManufacturingPractice/News/CON355490 (accessed January 24, 2015).
Google Scholar
12.↵
FDA. Guidance for Industry. Electronic Source Data in Clinical Investigations; FDA: Silver Spring, MD, USA, 2013.
Google Scholar
13.↵
FDA Inspection Guides. Glossary of Computer System Software Development Terminology. http://www.fda.gov/iceci/inspections/inspectionguides/ucm074875.htm (accessed January 24, 2015).
Google Scholar
14.↵
FDA. Guidance for Industry. Part 11, Electronic Records; Electronic Signatures—Scope and Application; FDA: Silver Spring, MD, USA, 2003.
Google Scholar
15.↵
1. Hickey C.
FDA works with China to ensure medical-product safety. FDA Voice. http://blogs.fda.gov/fdavoice/index.php/2014/04/fda-works-with-china-to-ensure-medical-product-safety/ (accessed January 24, 2015).
Google Scholar
16.↵
EMA. Roadmap to 2015: EMA Contribution to Science, Medicines and Health; London, UK, 2010.
Google Scholar
17.↵
EMA. EU GMPs. Medicinal Products for Human and Veterinary Use: Annex 11 Computerised Systems. SANCO/C8/AM/sl/ares(2010)1064599; Brussels, Belgium, 2011.
Google Scholar
18.↵
FDA. Guidance for Industry. Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring; FDA: Silver Spring, MD, USA, 2013.
Google Scholar
19.↵
FDA. Guidance for Industry. Product Development under the Animal Rule—Draft; FDA: Silver Spring, MD, USA, 2014.
Google Scholar
20.↵
Press Release: PIC/S Expert Circle on Active Pharmaceutical Ingredients (APIs); Rome, Italy; http://www.picscheme.org/bo/commun/upload/document/press-release-rome-2014-copy1.pdf (accessed January 24, 2015).
Google Scholar